Tag Archives: The Rockefeller University
Last week, we held our inaugural Advocacy Academy, bringing 12 postdoctoral researchers from across the U.S. to Washington, D.C. A two-day advocacy training program that culminated in Congressional visits with the participants’ representatives. We selected this group of motivated and concerned early-career scientists from a diversity of institutions, including Northeast Ohio Medical University, UCSF, Memorial Sloan-Kettering Cancer Center, Baylor College of Medicine, the University of Pennsylvania School of Nursing, Johns Hopkins University, Weill Cornell Medical College, the University of Washington and Banner Sun Health Research Institute, Eli Lilly and Company, as well as local researchers at the National Cancer Institute and National Institute of Allergy and Infectious Diseases. For these young researchers, sequestration and budget cuts have clamped down on available resources to investigate diseases in the lab and raised concerns about the viability of a future career in research. Feeling compelled to take action, these postdoctoral research fellows came to Washington to convey the personal and societal importance of medical and health research. And they did a terrific job. Continue reading →
Dear Research Advocate,
Yesterday, the House passed a budget for the remainder of the fiscal year that includes this year’s cuts from sequestration along with an additional one percent across-the-board cut. The bill now heads to the Senate for consideration, where we are likely to see higher funding levels than the House version, but with sequestration still in place. Congress seems anxious to avoid the brinksmanship and the government shutdown threats that have characterized past debates. While the less rancorous environment surrounding the CR is a welcome change, the complacency around sequestration is not. As research advocates, we cannot let these cuts stand.
Sequestration isn’t a one-year cut, it is ten years worth of cuts, none of which are evidence-based. We may be looking at the early stages of an elusive “grand bargain” as the president meets with Republican senators to discuss tax and entitlement reform – two key pieces for solving the deficit puzzle. Eliminating sequestration must be part of that bargain. In addition, we must ensure that funding for biomedical and health research, including the resources FDA needs to do its job, are assigned a high priority in fiscal year 2014. That should be reflected in the budget resolution and obviously in the FY 2014 funding bill.
None of this will be easy. Working together, advocates have raised the profile of medical research with policymakers and the media. We need to turn the volume up louder yet on it, while cultivating more champions in Congress. Continuing to engage the media is part of that equation. Some of the largest news outlets in the country including Fox News, NBC, and CBS, and a number that are new to our issue including Al Jazeera quoted Research!America when writing about sequestration’s impact on science. The Economist published a thoughtful piece about how cutting American health research will harm the world. Industry is adding its voice with an op-ed in Forbes coauthored by three legendary executives, including Research!America board member and former NIH director, Dr. Elias Zerhouni, Marc Tessier-Lavigne of The Rockefeller University and P. Roy Vagelos, Chairman of Regeneron Pharmaceuticals. I also want to highlight a letter that Dr. Herb Pardes, Executive Vice Chairman at New York Presbyterian and Research!America board member, sent to the President. He captures the very themes that will anchor our advocacy going forward.
At the same time as policymakers were cutting federally funded research dollars, researchers were delivering another astonishing breakthrough – the real possibility of a functional cure for HIV. This remarkable achievement, bringing us a step closer to a world free from the scourge of HIV/AIDS, would not have been possible were it not for NIH funding that supported the research and development of anti-retroviral drugs. The CDC is also in the news, with troubling warnings about the spread of “nightmare bacteria” – germs that can be deadly because they are resistant to traditional medicines. As CDC works to track and halt the spread of these germs and fulfill the numerous other public health functions for which they are responsible, the agency is not only contending with sequestration. Over the past several years, CDC has been subject to some of the deepest cuts of any health agency. Our Nation is fast approaching a tipping point. Are public health and safety and the progress borne of medical innovation priorities, or not?
As many of you already know our annual events are coming up next week! Please join us for the Annual Meeting (free of charge to members) to hear remarks from Rep. Joe Kennedy (D-MA), a freshman member of Congress who is already championing research, and also John Crowley, CEO of Amicus Therapeutics. I hope to see you all at our Annual Advocacy Awards Dinner later that evening – seats are selling fast, but still available.